In Specialty Pharma, First Horizon's Low Cost Sales Model
In 2003, after a string of bad luck that had sent its stock down 81%, First Horizon overhauled its management team and began to implement a new low-cost sales strategy. It appears to be working. First quarter 2004 income was $8.2 million, compared to a loss of almost $14 million a year ago. Prescriptions of its key product, calcium channel blocker nisoldipine (Sular), were up 10% in the quarter, and this was evidently enough to convince pharmaceutical company SkyePharma PLC to grant the specialty pharma US marketing rights to an unnamed cardiovascular product.
You may also be interested in...
Gene therapy remains attractive when data show new technologies can advance the field, but gene regulation, editing and RNA therapies are grabbing investors’ attention, panelists said at ARM’s Cell and Gene Meeting on the Mesa.
Gilead looks set to expand its lead position in the triple-negative breast cancer (TNBC) market in Europe with a positive opinion for Trodelvy from the CHMP.
Company seeks to avoid Medicaid “best price” implications by administering the program through an insurance policy with AIG, which is handling claims for refunds and processing payments.